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an Iranian 1000-bed hospital and to assess the activity of
commonly used antibiotics including nitrofuantoin against
VRE isolates.
Methods: This study was carried out between April 2002
and April 2006 in Milad Hospital of Tehran a 1000-bed non-
teaching hospital Only patients who had puria and signiﬁcant
bactteriuria included in our study. All isolates performed
identiﬁcation to species level by using routine bacterio-
logical methods and susceptibility testing performed by
disk diffusion method as recommended by Clinical Labo-
ratory Institute Standards (CLSI) Results: All urine isolates
were also tested for resistance to ampicillin, penicillin,
ciproﬂoxacin, erythromycin, tetracycline and norﬂoxacine.
Results: In Total 837 Enterococcus species were isolated
from UTI that 668 (79.8%) and 169 (20.2%) isolates were
E.faecalis and E.faecium respectively. Analysis of the col-
lected data revealed that 9.43% vancomycin resistant strains
were resistant to nitrofurantoin as well (6 out of 65), while
84.9% of the isolated entrococci (54 out 65) were van-
comycin resistant and nitrofurantoin sensitive resistance
among E.faecium were prevalent in comparison with E. fea-
clis isolates Study on the data also showed both vancomycin
and nitrofurantoin resistant isolate have higher frequency
rate in admitted patients compared with out-patients.
Conclusion: It is concluded that susceptibility approx-
imately 85% VRE to nitroforantoin still is the suitable
alternative drug for treatment urinary tract infections
caused by VRE.
doi:10.1016/j.ijid.2008.05.697
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Objective: The aim of this study was to determine
proﬁciency of Iranian microbiology laboratories for detec-
tion of methicillin resistant Staphylococcus aureus and
performance of susceptibility testing of this organism to
vancomycin.
Method: One strain of Staphylococcus aureus (ATCC
33591) were chosen from Iranian reference laboratories
collection. This strain lyophilized and distributed among
2282 clinical microbiology laboratories in country. We asked
all laboratories for identiﬁcation and susceptibility testing
against oxacillin (methicillin), vancomycin, chlorampheni-
col, erythromycin and tetracycline and return answers after
two weeks receipt of sample.
Results: Of 2282 laboratories contacted, 1509 (66.1%)
agreed to participate in our study and sent back their
results on time. The remaining 773 (33.9) laboratories did
not participated in our survey. Regarding to identiﬁcation
of S. aureus of 1509 laboratories 129 (8.54%) obtained the
maximum score (Three score), 1350 laboratories (89.4%)
obtained intermediate score (1—2.5) and the remaining 30
(1.98%) obtained zero score of points in otherwise this
group did not identiﬁed correctly S. aureus. The mean
score for identiﬁcation of S. aureus in country was 1.91
(Tehran 2,01 vs.1.91 other provinces). Of 1509 laborato-
ries 1349 (89.4%) performed correct susceptibility testing
for methicillin 88, laboratories (5.8%) could not determined
resistance of S. aureus to methicillin and 72 laboratories
did not performed susceptibility testing of S. aureus for
methicillin. Mean score of susceptibility testing for methi-
cillin was: 0.89 for country, 0.93 for Tehran and 0.87 for
other provinces. Proﬁciency in performance of susceptibil-
ity testing for vancomycinn varied between laboratories of
1509 laboratories, 594 (55.1.%) correctly performed sus-
ceptibility testing of S. aureus according to vancomycinn
and reported correct result, while 594 (39.4%) laboratories
reported incorrect results (the mean error) and 26 labora-
tories 1.7% did not perform susceptibility testing according
to vancomycin. Mean score of susceptibility testing for van-
comycin was: 0.59 for country and 0.68 for Tehran
Conclusion: Our study revealed that detection of MRSA
in clinical microbiology laboratories is satisfactory but the
majority of laboratories (40%) have difﬁculties in perfor-
mance of susceptibility testing of S. aureus according to
vancomycin.
doi:10.1016/j.ijid.2008.05.698
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Background: Activity of dalbavancin was compared to
other antimicrobials against a collection of Gram-positives
cultured from patients in the UK and Ireland. Dalbavancin is
a novel lipoglycopeptide with an extremely long elimination
half-life. Dalbavancin is projected for treatment of skin and
skin structure infections including those caused by S. aureus
(SA) and -haemolytic streptococci (BHS).
Methods: Sites in UK and Ireland were recruited to
test 60 strains of SA (50) and coagulase-negative staphylo-
cocci (CoNS; 10), including methicillin-resistant (MR) strains
and 15 BHS. Dalbavancin and vancomycin were tested by
Etest and results compared to other antimicrobial classes
tested by disk diffusion. Inducible clindamycin resistance
was determined by D-Test. QC strains were included during
each day of testing and comparison drug susceptibility was
calculated using CLSI criteria. Dalbavancin susceptibility was
deﬁned as ≤0.25mg/L.
Results: Dalbavancin and vancomycin inhibited all SA iso-
lates below deﬁned breakpoints with MIC90 values of 0.125
and 1.5mg/L, respectively. Except two CoNS with dalba-
vancin MIC values slightly above breakpoint (0.38mg/L), all
staphylococci were inhibited by dalbavancin, vancomycin
and linezolid. Most SA isolates were also susceptible to
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e259
tetracycline (96.4%) and gentamicin (99.3%). Staphylococci
included MRSA (35.7%) and MR-CoNS (68.4%); and MRSA iso-
lates were resistant to levoﬂoxacin (96%) and erythromycin
(74%). All clindamycin-susceptible SA had inducible resis-
tance. Dalbavancin (MIC90; 0.047mg/L) was 10-fold more
potent than vancomycin (MIC90; 0.5mg/L) against BHS.
Erythromycin susceptibility was 82% with a 25% inducible
clindamycin resistance.
Conclusions: The DECIDE study demonstrated in UK and
Ireland that dalbavancin has excellent activity and was more
potent when directly compared to vancomycin. Dalbavancin
was active against all MRSA, although the current suscepti-
bility proﬁles for other antimicrobial classes tested were of
great concern, particularly inducible clindamycin resistance
(100%). Monitoring dalbavancin activity should be continued
as this newer long-acting agent is introduced into EU clinical
practice.
doi:10.1016/j.ijid.2008.05.699
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Background: Dalbavancin activity was tested against iso-
lates from three medical centers in Italy between October
— December, 2007. Only reference quality and standardized
CLSI methods were used.
Methods: Susceptibility methods for agar diffusion were
applied by each investigator: Etest (ET; AB BIODISK) and
CLSI disk diffusion (DD) tests performed with concurrent QC
with repeated testing of strains showing unusual resistance
patterns such as linezolid, teicoplanin or dalbavancin-
non-susceptibility (MIC, >0.25mg/L). 225 strains were
tested against dalbavancin and teicoplanin by ET and
linezolid, cefoxitin, levoﬂoxacin, gentamicin, tetracycline,
erythromycin, clindamycin (plus D-test), penicillin and cef-
triaxone by DD. Dalbavancin susceptibility was deﬁned at
≤0.25mg/L.
Results: Dalbavancin showed high activity against the
151 S. aureus (SA; MIC range, ≤0.016—0.25mg/L), CoNS
(≤0.016—0.25mg/L) and -haemolytic streptococci (BHS;
≤0.016—0.094mg/L). This activity was 4-, 16- and ≥4-
fold greater than teicoplanin when comparing MIC90 values,
respectively. Susceptibility rates among SA were: linezolid
(97%), levoﬂoxacin (61%), erythromycin (43%), clindamycin
(51%), tetracycline (86%) and gentamicin (70%). Six linezolid-
non-susceptible strains were noted among SA and BHS but
all had zone diameters (19—20mm) near the breakpoint
(≥21mm). Teicoplanin-resistant CoNS and levoﬂoxacin-
resistant BHS were detected. A distinct trend toward higher
dalbavancin ET MIC results was observed, a probable techni-
cal reading error also noted for false-resistant DD linezolid
results for SA and BHS (six occurrences). D-test inducible-
resistant rates for clindamycin varied from 38 (BHS) to 78%
(SA).
Conclusions: Dalbavancin, a new long-acting glycol-
ipopeptide (once weekly dosing), demonstrated high activity
(MIC50 ranges, ≤0.016—0.19mg/L) against staphylococci and
BHS from Italy. The recorded MIC90 was 0.125mg/L, a con-
ﬁrmed ﬁnding suggesting a high MIC reading bias for ET. The
most elevated MIC results were at 0.25mg/L (breakpoint; 33
occurrences among SA). The exhibited dalbavancin potency
(4-fold greater than teicoplanin; only tested in Italy DECIDE
sample) covered all contemporary Gram-positive pathogens.
doi:10.1016/j.ijid.2008.05.700
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Background: Dalbavancin, a long-acting glycolipopep-
tide, was tested against clinical isolates from four hospitals
in Germany in the last quarter of 2007.
Methods: Investigators used standardized and reference-
quality agar diffusion methods including Etest (ET; AB
BIODISK) and CLSI disk diffusion (DD) tests with concur-
rent QC and repeated testing of strains showing unusual
resistance patterns such as linezolid resistance and van-
comycin or dalbavancin-non-susceptibility. 300 strains were
tested (200 S. aureus [SA], 40 coagulase-negative staphy-
lococci [CoNS], 60 -haemolytic streptococci [BHS] with
most being group A or S. pyogenes) against dalbavancin and
vancomycin by ET; and linezolid, cefoxitin (determination
of methicillin resistance), levoﬂoxacin, gentamicin, tetra-
cycline, erythromycin, clindamycin (plus D-test), penicillin
and ceftriaxone by DD. All German sites having acceptable
QC results were tabulated. Dalbavancin susceptibility was
deﬁned at ≤0.25mg/L.
Results: Dalbavancin exhibited excellent activity
against SA (MIC50/90, 0.047/0.125mg/L), CoNS (MIC50/90,
0.047/0.19mg/L) and BHS (MIC50/90, ≤0.016/0.032mg/L).
This activity was 16- to 32-fold greater than vancomycin.
MRSA rates were low (8%) but varied modestly from 4
to 12% among hospitals. S rates were: linezolid (100%),
levoﬂoxacin (55-83%), erythromycin (50—80%), and clin-
damycin (65—84%). D-test positive rates were 33—86% for
the SA, CoNS and BHS; overall clindamycin-resistant at
16% for SA, but nil for BHS. SA was also very susceptible
to gentamicin (95%) and tetracycline (93%). Methicillin
susceptibility or resistance did not inﬂuence dalbavancin
potency versus SA or CoNS. Highest recorded dalbavancin
MIC was 0.38mg/L, two conﬁrmed staphylococci from
Frankfurt. Some German centers read Etest results higher
(0.5—1.0 log2) than other laboratories in Europe.
